Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| ANBL09P1 | COG | A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma: A Limited Institution Pilot Study | Pediatric CIRB | Available to Open | |
| ANBL1021 | COG | Feasibility/Phase II Study of hu14.18-IL2 immunocytokine + GM-CSF and Isotretinoin in Patients with Relapsed or Refractory Neuroblastoma: A Groupwide Phase II Study | Pediatric CIRB | Completed | |
| ANBL1221 | COG | A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864; IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038; IND# 4308) in Children with Refractory; Relapsed or Progressive Neuroblastoma | Pediatric CIRB | Completed | |
| ANBL1232 | COG | Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study | Pediatric CIRB | Available to Open | |
| ANBL12P1 | COG | Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma | Pediatric CIRB | Available to Open | |
| ANBL1531 | COG | A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Standard Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379) | Pediatric CIRB | Available to Open | |
| ANBL17P1 | COG | A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, dinutuximab) (NSC# 764038, IND# 4308) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma | Pediatric CIRB | Available to Open | |
| ANBL1821 | COG | A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed, Refractory or Progressive Neuroblastoma | Pediatric CIRB | Available to Open | |
| ANBL19P1 | COG | A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma | Pediatric CIRB | Available to Open | |
| ANBL2131 | COG | A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma | Cancer Prevention and Control CIRB | Available to Open |